ERBB2 and breast carcinoma: HER2-positive breast cancer is characterized by its aggressive nature, poor prognosis, reduced sensitivity to anthracycline-based chemotherapy, and better response to HER2-targeted therapies such as trastuzumab, lapatinib, and pertuzumab [59,60], which significantly improve disease-free and overall survival rates.